ARQT - Arcutis Biotherapeutics Inc
23.95
-0.640 -2.672%
Share volume: 630,722
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$24.59
-0.64
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-14-2024 | 11-06-2024 | 02-25-2025 | 05-06-2025 | 10-28-2025 | 02-25-2026 | |
| Assets | ||||||||
| Total Assets | 478.541 M | 444.759 M | 437.354 M | 348.889 M | 344.105 M | 370.977 M | 432.973 M | |
| Current Assets | 468.062 M | 434.591 M | 423.720 M | 335.820 M | 323.671 M | 349.224 M | 411.232 M | |
| Inventories | 13.247 M | 13.880 M | 14.015 M | 14.526 M | 16.614 M | 22.419 M | 22.634 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 213.769 M | 278.167 M | 195.710 M | 156.620 M | 144.984 M | 143.948 M | 178.075 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 190.097 M | 84.270 M | 134.851 M | 71.335 M | 53.104 M | 47.120 M | 42.907 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 1.369 M | 1.347 M | 1.186 M | 1.041 M | 1.496 M | 1.215 M | 1.043 M | |
| Other Assets | 9.110 M | 8.821 M | 12.448 M | 12.028 M | 18.938 M | 20.538 M | 20.698 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 478.541 M | 444.759 M | 437.354 M | 348.889 M | 344.105 M | 370.977 M | 432.973 M | |
| Total liabilities | 253.599 M | 258.332 M | 280.713 M | 191.348 M | 201.447 M | 212.904 M | 243.494 M | |
| Total current liabilities | 47.309 M | 51.352 M | 172.426 M | 81.013 M | 91.129 M | 99.770 M | 129.838 M | |
| Accounts Payable | 12.969 M | 7.943 M | 19.325 M | 14.220 M | 24.529 M | 5.795 M | 12.528 M | |
| Other liabilities | 3.487 M | 3.172 M | 3.192 M | 3.132 M | 2.700 M | 5.636 M | 5.697 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 202.803 M | 203.808 M | 105.095 M | 107.203 M | 107.618 M | 107.498 M | 107.959 M | |
| Other liabilities | 3.487 M | 3.172 M | 3.192 M | 3.132 M | 2.700 M | 5.636 M | 5.697 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 224.942 M | 186.427 M | 156.641 M | 157.541 M | 142.658 M | 158.073 M | 189.479 M | |
| Common stock | 1.242 B | 1.256 B | 1.267 B | 1.279 B | 1.290 B | 1.314 B | 1.328 B | |
| Retained earnings | -1.017 B | -1.070 B | -1.111 B | -1.122 B | -1.147 B | -1.155 B | -1.138 B |